Medical Condition News

RSS

Scientists discover natural mechanism to discard amyloid protein

Chemists at the University of California, San Diego, have identified how a protein that accumulates in the brains of people with Alzheimer's disease interferes with the ability of cells to get rid of debris. They also found a natural mechanism by which this protein, amyloid beta, itself may be discarded.

9 Sep 2010

NIH awards second $8 million grant for research into health effects of botanical estrogens

An ongoing research initiative into the health effects of botanical estrogens will get an $8 million boost from the National Institutes of Health.

9 Sep 2010

Hemispherx Biopharma to present clinical data on XMRV retrovirus at International Workshop

Hemispherx Biopharma, Inc. will present new clinical data on the possible inter-relationships of XMRV positivity/chronic fatigue syndrome/Ampligen responsiveness at the 1st International Workshop on XMRV being held at the National Institutes of Health in Bethesda, MD, on September 7 and 8, 2010.

9 Sep 2010

ImmunoCellular Therapeutics announces long-term data from ICT-107 Phase I clinical trial for GBM

ImmunoCellular Therapeutics, a biotechnology company focused on the development of novel immune-based cancer therapies, today announced long-term data from a Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.

9 Sep 2010

ReVision Optics completes enrollment, initial follow up in PresbyLens Phase I clinical trial for presbyopia

ReVision Optics, a leading company in the research, development and manufacture of implantable medical devices designed to assist patients that need reading glasses, announced today that it has completed enrollment and initial follow up in Phase I of its US clinical trial and has filed for expansion. The clinical trial is for the study of the PresbyLens, recently renamed Vue+, for the improvement of near vision in patients with presbyopia, the age-related loss of near vision.

9 Sep 2010

AERI merges with AHEADD to support communities impacted by Autism Spectrum Disorder

The Autism Education and Research Institute (AERI), an organization committed to providing consultative services that incorporates innovative current research in the field of autism, announces their merging with Achieving in Higher Education with Autism / Developmental Disabilities (AHEADD) in order to support consumers, families, schools, and their surrounding communities who are impacted by Autism Spectrum Disorders (ASD).

9 Sep 2010

EDAP reports clinical outcomes of Ablatherm-HIFU treatment in prostate cancer patients

EDAP TMS SA, the global leader in therapeutic ultrasound, today reported favorable clinical outcomes for patients treated with Ablatherm-HIFU.

9 Sep 2010

Irregular body weight increases mortality risk in women with colon cancer: Study

Postmenopausal women diagnosed with colon cancer may be at increased risk of death if they fail to maintain a healthy body weight before cancer diagnosis, according to a study published in the September issue of Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

9 Sep 2010

Researchers synthesize new compounds to reduce A-beta 42 peptide in Alzheimer's disease

A team of scientists, led by University of California, San Diego School of Medicine researchers, has synthesized hundreds of new compounds with the potential of reducing the production of the A-beta 42 peptide, a primary component of Alzheimer's disease (AD).

9 Sep 2010

$GSK, Genmab commence ofatumumab Phase III study in rituximab refractory patients with indolent B-NHL$

GSK, Genmab commence ofatumumab Phase III study in rituximab refractory patients with indolent B-NHL

GlaxoSmithKline and Genmab A/S announced today the start of a Phase III study in patients with indolent B-cell non-Hodgkin's lymphoma (B-NHL) who did not respond to or progressed during, or within 6 months of a rituximab containing regimen.

9 Sep 2010

GE Healthcare's flutemetamol phase 2 study results published in 'Annals of Neurology'

GE Healthcare announced today that results from its multicenter phase 2 study of flutemetamol were published in the September issue of Annals of Neurology. Flutemetamol is an investigational positron emission tomography (PET) imaging agent being developed by GE Healthcare, in the field of brain imaging.

9 Sep 2010

Progenics commences Phase 3 trial of oral methylnaltrexone for opioid-induced constipation

Progenics Pharmaceuticals, Inc. today announced the initiation of an international 700-patient, phase 3 trial of oral methylnaltrexone in patients with chronic, non-cancer pain who are experiencing constipation as a result of their opioid-pain management regimens. The goal of the study is to evaluate the safety and efficacy of oral methylnaltrexone to treat opioid-induced constipation (OIC) in this patient setting.

8 Sep 2010

MAP Pharmaceuticals completes 12 months of treatment in LEVADEX open-label safety trial

MAP Pharmaceuticals, Inc. today announced that all non-asthmatic patients and a subset of asthmatic patients have completed 12 months of treatment in the open-label safety trial of LEVADEX™. In addition, the Company has completed patient treatment in a thorough QT trial, the last trial necessary to support a New Drug Application (NDA) for LEVADEX.

8 Sep 2010

MAP Pharmaceuticals reports results from PD trial that compares effects of LEVADEX, IV DHE

MAP Pharmaceuticals, Inc. today reported results from a pharmacodynamics trial comparing the acute effects on pulmonary artery pressure of LEVADEX, dihydroergotamine mesylate administered intravenously and placebo. In the trial, there was no statistically significant difference between the LEVADEX and placebo groups in the primary endpoint of pulmonary artery pressure over two hours after administration.

8 Sep 2010

Update on Enobia Pharma's effort to develop ENB-0040 for treating HPP patients

Enobia Pharma today provided an update on key developments in its comprehensive effort to develop ENB-0040 (asfotase alfa), an experimental bone-targeted enzyme replacement therapy, for the treatment of hypophosphatasia. Hypophosphatasia is a rare, inherited, and sometimes fatal metabolic bone disease that affects individuals of all ages.

8 Sep 2010

Positive results from YM BioSciences' CYT997 Phase I study for vascular disruption in tumors

YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.

8 Sep 2010

Perrigo receives FDA approval to manufacture, market Imiquimod Cream, 5%

Perrigo Company announced it received FDA approval from the U.S. Food and Drug Administration to manufacture and market Imiquimod Cream, 5%. Perrigo will vertically integrate this product with their own API.

8 Sep 2010

Mary Ann Liebert launches Childhood Obesity journal to promote clinical advances

Publisher Mary Ann Liebert announced the launch of Childhood Obesity to provide physicians, nurses, dietitians, diabetes educators, nutritionists, psychologists, educators and school nurses, community organizers, and policymakers with effective prevention and treatment strategies that promote environmental and policy changes, patient education and motivation tools, and clinical advances in the field.

8 Sep 2010

Virginia Commonwealth University experts available to discuss childhood obesity

Virginia Commonwealth University has experts available in pediatric obesity, psychology, medicine and fashion to discuss a variety of topics including healthy eating, physical activity, lifestyle programs and strategies, trends and causes related to childhood obesity during the month of September.

8 Sep 2010

PLX4032 trial shows high degree of selectivity to achieve tumor shrinkage

Plexxikon today announced publication of key data in this week's edition of Nature demonstrating that the high degree of selectivity of PLX4032 (RG7204) enables substantial RAF/MEK/ERK pathway inhibition, which may be necessary to achieve significant tumor shrinkage and clinical response in patients with BRAF mutant melanoma.

8 Sep 2010

Medical Condition News

Scientists discover natural mechanism to discard amyloid protein

NIH awards second $8 million grant for research into health effects of botanical estrogens

Hemispherx Biopharma to present clinical data on XMRV retrovirus at International Workshop

ImmunoCellular Therapeutics announces long-term data from ICT-107 Phase I clinical trial for GBM

ReVision Optics completes enrollment, initial follow up in PresbyLens Phase I clinical trial for presbyopia

AERI merges with AHEADD to support communities impacted by Autism Spectrum Disorder

EDAP reports clinical outcomes of Ablatherm-HIFU treatment in prostate cancer patients

Irregular body weight increases mortality risk in women with colon cancer: Study

Researchers synthesize new compounds to reduce A-beta 42 peptide in Alzheimer's disease

GSK, Genmab commence ofatumumab Phase III study in rituximab refractory patients with indolent B-NHL

GE Healthcare's flutemetamol phase 2 study results published in 'Annals of Neurology'

Progenics commences Phase 3 trial of oral methylnaltrexone for opioid-induced constipation

MAP Pharmaceuticals completes 12 months of treatment in LEVADEX open-label safety trial

MAP Pharmaceuticals reports results from PD trial that compares effects of LEVADEX, IV DHE

Update on Enobia Pharma's effort to develop ENB-0040 for treating HPP patients

Positive results from YM BioSciences' CYT997 Phase I study for vascular disruption in tumors

Perrigo receives FDA approval to manufacture, market Imiquimod Cream, 5%

Mary Ann Liebert launches Childhood Obesity journal to promote clinical advances

Virginia Commonwealth University experts available to discuss childhood obesity

PLX4032 trial shows high degree of selectivity to achieve tumor shrinkage

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Latest News